Bill Lundberg

Bill Lundberg serves as President and CEO of Merus N.V. since March 2019, concurrently holding positions as Independent Director at Vor Biopharma and Q32 Bio Inc., and as Partner at Cold Spring Partners, LLC. With a strong background in biopharmaceuticals, Bill Lundberg has previously been an Independent Director at 1928 Diagnostics and Meridian Academy, and held key roles at CRISPR Therapeutics, including Chair of the Scientific Advisory Board and Chief Scientific Officer. Bill Lundberg's experience also includes tenure as Vice President of Translational Medicine at Alexion Pharmaceuticals and Chief Medical Officer at Taligen Therapeutics. Educational credentials comprise an MD from Stanford University School of Medicine, a BS in Biology from the Massachusetts Institute of Technology, and an MBA from the Isenberg School of Management at U Mass.